Ionis Pharmaceuticals (NASDAQ:IONS) announces that collaboration partner Bayer (OTCPK:BAYRY) has decided to advance antisense candidate IONIS-FXI-Lrx for the potential treatment of clotting disorders.
Under their May 2015 agreement, Bayer has
exclusive rights to develop Ionis’ Factor XI-targeting programs for
clotting disorders. Its decision to proceed with this candidate triggers
a $10M milestone payment to Ionis, who is eligible for additional
milestones and tiered royalties in the low-to-high 20% range on gross
margins.
https://seekingalpha.com/news/3504651-ionis-earns-10m-milestone-bayer-advancement-clotting-disorder-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.